Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).
Rinvoq, a JAK inhibitor, from AbbVie expanded its label in Japan to include non-radiographic axial spondyloarthritis (nr-axSpA) inadequately controlled with existing therapies
AbbVie announced positive top-line data from the SELECT-PsA 2 Phase III study . In this study, both doses of Rinvoq...
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for Rinvoq (upadacitinib) in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
AbbVie announced positive top-line results from the Phase III SELECT-PsA 1 clinical trial. In this study, both doses of Rinvoq...
AbbVie announced Rinvoq (upadacitinib 15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase III study of Rinvoq in atopic dermatitis.
The National Institute for Health and Care Excellence (NICE) has recommended Rinvoq (upadacitinib) from AbbVie together with standard-of-care methotrexate, for...
AbbVie has announced that the FDA has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for...